相关实验视频

Updated: Jan 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[对抗EGFR治疗的现代方法]

E V Dudkina¹, A I Nadyrova^1,2, S A Luginskaya¹

¹Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 420008 Russia.

Molekuliarnaia biologiia

|January 1, 2026

概括

针对表皮生长因子受体 (EGFR) 对于癌症治疗至关重要. 本综述探讨了抗EGFR药物,耐药性机制以及包括核糖核酶 (RNases) 在内的新型组合策略,以提高抗瘤疗效.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

皮表皮生长因子受体 (EGFR) 信号传递对细胞生长,存活和增殖至关重要.
EGFR通路的失调驱动癌症的发展,进展和转移.
EGFR是开发抗癌药物的首要目标.

研究的目的:

审查当前的抗EGFR疗法及其局限性.
讨论获得对EGFR向药物的耐药性机制.
探索组合策略和新药,以改善癌症治疗.

主要方法:

审查关于抗EGFR疗法的现有文献.
对EGFR向癌症治疗中的耐药性机制的分析.
评估组合治疗策略和新兴药物,如RNases.

主要成果:

已经开发了几代抗EGFR药物 (单克隆抗体,TKI,免疫毒素).
获得的耐药性和KRAS突变限制了治疗反应.
组合疗法和像RNases这样的药物显示出克服耐药性的前景.

结论:

针对EGFR的疗法是必不可少的,但由于药物耐药性而面临挑战.
组合策略对于提高抗EGFR治疗的疗效至关重要.
核糖核酶 (RNases) 是一种有前途的新型抗瘤药物.

关键词:

欧洲农业基金会 (EGFR) 是一个.这里是BinaseBinaseBinase 药物耐药性耐药性药物耐药性皮肤上生长因子受体.一个单克隆抗体.核糖核酸酶是一种核糖核酸酶.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...